CMS spinoff Dermavon files for Hong Kong IPO
Dermavon, the dermatology arm of China Medical System, filed for a Hong Kong listing with 2024 revenue of RMB 618 million, led by vitiligo drug ruxolitinib and other niche therapies. As it steps out on its own, questions remain around R&D depth and pipeline access without support from CMS.